These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
353 related articles for article (PubMed ID: 26804643)
41. Exploration of potential EGFR inhibitors: a combination of pharmacophore-based virtual screening, atom-based 3D-QSAR and molecular docking analysis. Sudha A; Srinivasan P; Rameshthangam P J Recept Signal Transduct Res; 2015 Apr; 35(2):137-48. PubMed ID: 25069678 [TBL] [Abstract][Full Text] [Related]
42. Development of 3D-QSAR Model for Acetylcholinesterase Inhibitors Using a Combination of Fingerprint, Molecular Docking, and Structure-Based Pharmacophore Approaches. Lee S; Barron MG Toxicol Sci; 2015 Nov; 148(1):60-70. PubMed ID: 26202430 [TBL] [Abstract][Full Text] [Related]
43. Molecular dynamics and 3D-QSAR studies on indazole derivatives as HIF-1α inhibitors. Singh Y; Sanjay KS; Kumar P; Singh S; Thareja S J Biomol Struct Dyn; 2023 May; 41(8):3524-3541. PubMed ID: 35318905 [TBL] [Abstract][Full Text] [Related]
44. Discovery of 2-(3,4-dialkoxyphenyl)-2-(substituted pyridazin-3-yl)acetonitriles as phosphodiesterase 4 inhibitors with anti-neuroinflammation potential based on three-dimensional quantitative structure-activity relationship study. Huang C; Zhong QP; Tang L; Wang HT; Xu JP; Zhou ZZ Chem Biol Drug Des; 2019 Apr; 93(4):484-502. PubMed ID: 30588755 [TBL] [Abstract][Full Text] [Related]
45. In silico approaches to identify novel myeloid cell leukemia-1 (Mcl-1) inhibitors for treatment of cancer. Ren JX; Li CP; Zhou XL; Cao XS; Xie Y J Biomol Struct Dyn; 2018 Jul; 36(9):2424-2435. PubMed ID: 28714799 [TBL] [Abstract][Full Text] [Related]
46. Pharmacophore- based virtual screening, 3D- QSAR, molecular docking approach for identification of potential dipeptidyl peptidase IV inhibitors. Shah BM; Modi P; Trivedi P J Biomol Struct Dyn; 2021 Apr; 39(6):2021-2043. PubMed ID: 32242496 [TBL] [Abstract][Full Text] [Related]
48. Discover potential inhibitors for PFKFB3 using 3D-QSAR, virtual screening, molecular docking and molecular dynamics simulation. Bao Y; Zhou L; Dai D; Zhu X; Hu Y; Qiu Y J Recept Signal Transduct Res; 2018; 38(5-6):413-431. PubMed ID: 30822195 [TBL] [Abstract][Full Text] [Related]
49. Pharmacophore modeling, 3D-QSAR, and in silico ADME prediction of N-pyridyl and pyrimidine benzamides as potent antiepileptic agents. Malik R; Mehta P; Srivastava S; Choudhary BS; Sharma M J Recept Signal Transduct Res; 2017 Jun; 37(3):259-266. PubMed ID: 27607834 [TBL] [Abstract][Full Text] [Related]
50. Modeling ligand-receptor interaction for some MHC class II HLA-DR4 peptide mimetic inhibitors using several molecular docking and 3D QSAR techniques. Wei HY; Tsai KC; Lin TH J Chem Inf Model; 2005; 45(5):1343-51. PubMed ID: 16180911 [TBL] [Abstract][Full Text] [Related]
51. Validation of TZD Scaffold as Potential ARIs: Pharmacophore Modeling, Atom-based 3D QSAR and Docking Studies. Dahiya L; Mahapatra MK; Kaur R; Kumar V; Kumar M Comb Chem High Throughput Screen; 2017; 20(4):310-320. PubMed ID: 28302016 [TBL] [Abstract][Full Text] [Related]
52. Identification of Potent Small-Molecule PCSK9 Inhibitors Based on Quantitative Structure-Activity Relationship, Pharmacophore Modeling, and Molecular Docking Procedure. Mahmoudi A; Butler AE; Banach M; Jamialahmadi T; Sahebkar A Curr Probl Cardiol; 2023 Jun; 48(6):101660. PubMed ID: 36841313 [TBL] [Abstract][Full Text] [Related]
53. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation. Halder AK; Saha A; Saha KD; Jha T J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685 [TBL] [Abstract][Full Text] [Related]
54. Identification of novel phosphodiesterase-4D inhibitors prescreened by molecular dynamics-augmented modeling and validated by bioassay. Li Z; Cai YH; Cheng YK; Lu X; Shao YX; Li X; Liu M; Liu P; Luo HB J Chem Inf Model; 2013 Apr; 53(4):972-81. PubMed ID: 23517293 [TBL] [Abstract][Full Text] [Related]
55. Insight parameter drug design for human β-tryptase inhibition integrated molecular docking, QSAR, molecular dynamics simulation, and pharmacophore modelling studies of α-keto-[1,2,4]-oxadiazoles. Yu CX; Tan JW; Rullah K; Imran S; Tham CL J Biomol Struct Dyn; 2023; 41(22):12978-12996. PubMed ID: 36709457 [TBL] [Abstract][Full Text] [Related]
56. An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies. Kashyap K; Kakkar R J Biomol Struct Dyn; 2020 Jan; 38(1):48-65. PubMed ID: 30633630 [TBL] [Abstract][Full Text] [Related]
57. Combined ligand and structure-based approaches on HIV-1 integrase strand transfer inhibitors. Reddy KK; Singh SK Chem Biol Interact; 2014 Jul; 218():71-81. PubMed ID: 24792351 [TBL] [Abstract][Full Text] [Related]
58. Rational design of methicillin resistance staphylococcus aureus inhibitors through 3D-QSAR, molecular docking and molecular dynamics simulations. Ballu S; Itteboina R; Sivan SK; Manga V Comput Biol Chem; 2018 Apr; 73():95-104. PubMed ID: 29475176 [TBL] [Abstract][Full Text] [Related]
59. Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors. Tripathi SK; Muttineni R; Singh SK J Theor Biol; 2013 Oct; 334():87-100. PubMed ID: 23727278 [TBL] [Abstract][Full Text] [Related]
60. Exploring the Role of Water Molecules in the Ligand Binding Domain of PDE4B and PDE4D: Virtual Screening Based Molecular Docking of Some Active Scaffolds. Singh P; Mishra M; Agarwal S; Sau S; Iyer AK; Kashaw SK Curr Comput Aided Drug Des; 2019; 15(4):334-366. PubMed ID: 30394213 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]